Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

BA, Physiological Sciences, 2008-11

RosiePigott.jpgRosie Mason undertook a Physiology BA at Oxford, supervised by Piers Nye and John Stein, where she completed a first-class dissertation project and was awarded the Periam Prize (2010) and Brackenbury Exhibition (2009 & 2010) for exceptional academic achievement in Medical Sciences.

Since graduating in 2011, she has pursued a career in medicines development in both the public and private sector. After two years at a think-tank (Collaboration for the Advancement of Sustainable Medical Innovation) funded by the Wellcome Trust (2012-14), which shaped the Adaptive Licensing / Early Access to Medicines policy, she moved to strategic consulting for a boutique life sciences advisory firm called Kinapse. There, she led global projects across many topics, including patient engagement. One of her career highlights is her time in Tokyo establishing a public-private forum to explore the patient group landscape in Japan. After working with more than 20 different clients in her consulting career across multiple functional areas, she decided to specialise in clinical trial operations for a mid-size company with a demonstrated track record of patient-centricity.

She is now Head of Clinical Trial Excellence at global biopharmaceutical company, Ipsen, where she works to improve the quality, speed and efficiency of studies to deliver innovative medicines for patients. Ipsen has a specialised portfolio in oncology, neuroscience and rare disease therapy areas, where there is a high level of unmet medical need. “As a rare disease patient myself, I am passionate about embedding the patient perspective at all stages of medicines development. I believe that being a part of the industry is one of the best ways to incorporate the patient voice and develop innovative medicines for those who need it most. Pharma as a whole is still behind other industries when it comes to putting patients at the center of research and development. I’m part of the new wave of thinking that’s driving a cultural shift to try and change that.” (Rosie Mason).